ImmunoGen Signs 2nd Licensing Deal with Amgen
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
983
Positive Rheumatoid Arthritis Data for UCB, Trubion, Others
Data presented this weekend at the American College of Rheumatology’s annual meeting indicated that rheumatoid arthritis patients who adhered to a prescription drug regimen had better medical outcomes and lower medical costs.